Mesa Laboratories Inc /Co/
MLAB Nasdaq· Industrial Instruments For Measurement, Display, And Control
Last close · Oct 26, 2026
$129.87
KIRA · Stoqly’s AI analyst, in plain words
- Mesa Laboratories Inc /Co/ had $249M of revenue in fiscal 2026, up 3.4% on the year before. Over five years, revenue changed +13.2% a year on average.
- Its operating margin was 7.4%, up 0.7 pts: of every 100 in sales, about 7 is left after running the business.
- Mesa Laboratories Inc /Co/ made $6.7M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew −9.3% a year.
- Free cash flow was $39.6M in fiscal 2026, 15.9% of revenue.
- Mesa Laboratories Inc /Co/ returned $3.5M to shareholders in fiscal 2026, 9% of free cash flow. The diluted share count rose 2.7%.
- Mesa Laboratories Inc /Co/ owes $40.6M more than it holds in cash, about 1.7 years of operating profit.
Market cap
$748M
P/E
152.8x
Revenue
$249M
Net income
$6.7M
Free cash flow
$39.6M
Operating margin
7.4%
Mesa Laboratories Inc /Co/ in 30 seconds · fiscal 2026
Are sales growing?
+3.4%
Only a little. Sales grew 3.4% last year.
Does it make a profit?
2.7%
A little. It keeps 2.7% of every sale as profit.
Does profit turn into cash?
15.9%
Yes. 15.9% of sales ends up as free cash.
Is debt under control?
1.7x
Keep an eye on it. Repaying its debt would take 1.7 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
152.8x
One share costs 152.8 times its yearly profit per share.
What Mesa Laboratories Inc /Co/ does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · Jun 3, 2026
- Legal name
- MESA LABORATORIES INC /CO/
- CIK
- 0000724004
Mesa Laboratories Inc /Co/ · MLAB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $184M | $219M | $216M | $241M | $249M |
| Revenue growth | 37.6% | 18.8% | −1.3% | 11.5% | 3.4% |
| Gross margin | 59.2% | 61.0% | 61.6% | 62.6% | 63.5% |
| Operating margin | 2.6% | 1.5% | −125.9% | 6.8% | 7.4% |
| Net income | $1.9M | $0.9M | −$254M | −$2.0M | $6.7M |
| Net margin | 1.0% | 0.4% | −117.6% | −0.8% | 2.7% |
| Diluted EPS | $0.35 | $0.17 | −$47.20 | −$0.36 | $1.21 |
| Cash | |||||
| Cash from operations | $39.2M | $28.0M | $44.1M | $46.8M | $42.8M |
| Capital expenditure | $4.4M | $4.5M | $2.6M | $4.2M | $3.3M |
| Free cash flow | $34.8M | $23.4M | $41.6M | $42.6M | $39.6M |
| FCF margin | 18.9% | 10.7% | 19.2% | 17.7% | 15.9% |
| Dividends paid | $3.3M | $3.4M | $3.4M | $3.5M | $3.5M |
| Share count change | 4.1% | 0.5% | 0.5% | 0.6% | 2.7% |
| Debt and strength | |||||
| Cash and short-term investments | $49.3M | $32.9M | $28.2M | $27.3M | $26.9M |
| Debt incl. finance leases | — | — | — | $71.3M | $67.5M |
| Shareholders' equity | $394M | $393M | $145M | $160M | $186M |
| Net debt / EBITDA | — | — | — | 2.0x | 1.7x |
| Current ratio | 2.6x | 2.7x | 2.5x | 0.6x | 1.7x |
| Interest coverage | 1.2x | 0.7x | −47.8x | 1.4x | 1.7x |
| Returns and quality | |||||
| Return on capital | — | — | — | 5.2% | 5.3% |
| Return on equity | 0.5% | 0.2% | −94.4% | −1.3% | 3.9% |
| Piotroski F-score | 4 | 6 | 4 | 5 | 8 |
| Altman Z'' | 2.4 | 2.7 | −4.0 | −1.5 | 0.4 |
Insiders bought, 12 months
$1.4M
4 insiders
Insiders sold, 12 months
$1.6M
4 insiders
Of sales under plans
32%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mesa Laboratories Inc /Co/ · MLAB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $129.87 a share, the company is worth $748M: 152.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000724004). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.